Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKinsey
McKesson
Medtronic
Express Scripts

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR TROGLITAZONE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Troglitazone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003058 ↗ Troglitazone in Treating Patients With Liposarcoma Completed National Cancer Institute (NCI) Phase 2 1997-06-01 Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.
NCT00003058 ↗ Troglitazone in Treating Patients With Liposarcoma Completed Dana-Farber Cancer Institute Phase 2 1997-06-01 Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.
NCT00116545 ↗ TART - Troglitazone Atherosclerosis Regression Trial Completed Parke-Davis Phase 2/Phase 3 1997-01-01 The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
NCT00242177 ↗ Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability Completed Takeda Pharmaceuticals North America, Inc. Phase 1 2003-10-01 The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients.
NCT00242177 ↗ Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability Completed University of Illinois at Chicago Phase 1 2003-10-01 The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients.
NCT00290394 ↗ Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients Completed Baskent University Phase 4 2004-03-01 The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.
NCT00412126 ↗ Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI Completed Heart and Stroke Foundation of Canada N/A 2002-07-01 Coronary artery disease is a process that results in "hardening of the arteries". When the arteries that supply blood and oxygen to your heart muscle become clogged or narrowed, a heart attack may result, or you may feel chest discomfort (angina) - sometimes even while resting. One approach to treating this condition is a balloon procedure known as coronary angioplasty. The major limitation of coronary angioplasty is renarrowing of the artery (restenosis) in the first six months following the procedure requiring either repeat angioplasty or referral for bypass surgery. Patients with diabetes have always been identified as having higher rates of restenosis and poor outcomes following angioplasty, despite some important scientific advances. We think that the level of blood sugar control at the time of angioplasty and in the following months may be related to the extent of restenosis. We expect that a reduction in blood sugar with insulin may, in turn, reduce the restenosis process and improve your long-term outcome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Troglitazone

Condition Name

Condition Name for Troglitazone
Intervention Trials
Diabetes Mellitus, Type 2 4
Type 2 Diabetes Mellitus 2
Diabetes Mellitus 2
Impaired Glucose Tolerance 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Troglitazone
Intervention Trials
Diabetes Mellitus 9
Diabetes Mellitus, Type 2 8
Glucose Intolerance 2
Hypertriglyceridemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Troglitazone

Trials by Country

Trials by Country for Troglitazone
Location Trials
United States 12
India 7
Italy 7
Canada 6
Malaysia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Troglitazone
Location Trials
California 3
Texas 2
Massachusetts 1
Utah 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Troglitazone

Clinical Trial Phase

Clinical Trial Phase for Troglitazone
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Troglitazone
Clinical Trial Phase Trials
Completed 14
Terminated 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Troglitazone

Sponsor Name

Sponsor Name for Troglitazone
Sponsor Trials
GlaxoSmithKline 3
Canadian Institutes of Health Research (CIHR) 3
Drug Safety and Effectiveness Network, Canada 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Troglitazone
Sponsor Trials
Other 21
Industry 8
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Medtronic
Colorcon
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.